WOUNDCARE FUND — WEEKLY PERFORMANCE SNAPSHOT
WoundCare Fund: -1.75% NASDAQ: +0.41% | S&P 500: +0.48% | Dow Jones: +1.07%
The WoundCare Fund closed the week down -1.75%, lagging a modestly positive broader market.
Not a macro story this week — this was company-specific giveback after prior runs.
Key Movers — Downside
Tela Bio — -15.07% After a sharp prior rally, this looks like classic small-cap giveback. Investors are still calibrating growth expectations around OviTex adoption and margin trajectory. When visibility isn't crystal clear, these names tend to swing hard both ways.
Avita Medical — -13.23% Another high-beta name pulling back after a major run. When expectations reset even slightly around procedural growth or near-term execution, Avita tends to move aggressively in either direction.
Celularity — -9.68% Continued volatility reflects the early-stage nature of its placental-derived cell therapy platform. Sentiment remains tightly tied to clinical progress, partnerships, and long-term commercialization pathways.
Organogenesis — -8.63% Ongoing pressure tied to reimbursement and utilization concerns in the skin substitute segment. Still firmly in "show me" mode.
Key Mover — Upside
Advanced Medical Solutions — +13.69% The outlier this week. Likely driven by steady execution and investor preference for profitable, scaled wound care platforms. In a choppy tape, consistency gets rewarded.
OPENING SHOT
A Week of Reckoning, Resilience, and a Bioresorbable Moment That Matters
The market gave back last week's gains across most wound care names — and that's fine. The underlying signals didn't reverse. They got clearer.
Sanuwave's Q1 preliminary numbers confirmed what the sector has felt for months: the reimbursement reset in skin substitutes and allografts is real, disruptive, and not fully resolved. CEO Morgan Frank called it "a sort of reckoning in the wound care space" as practitioners came to terms with significant changes in reimbursement for skin substitutes and allografts, causing many to pause or pull back. That's an honest read from someone close to the clinical floor.
But the more important story this week isn't the noise. It's what's being built through it. MediWound is assembling the clinical and commercial infrastructure for a genuine SANTYL challenge. Efemoral Medical dropped three-year vascular data that may be the most important femoropopliteal result since the DCB era. And MiMedx just restructured its cost base in a way that tells you exactly where the market pressure is landing — and where it isn't.
Also in the feed this week: an AI-designed antibiotic that cleared a drug-resistant wound infection in animal models. That story belongs in your peripheral vision.
BTK INNOVATION INDEX — 283 COMPANIES. ONE INDEPENDENT SCORE.
We rank the companies shaping this market across six proprietary dimensions. Every company scored on merit. No exceptions.
If you want to know where EscharEx, EVSS, Sanuwave, or MiMedx sit in the broader competitive landscape, the Index has the answer.
WOUND CARE
Commercial | MediWound Gains Ground as EscharEx Challenges a $2.5B Status Quo
In a head-to-head subgroup analysis from MediWound's Phase II ChronEx trial, 63% of patients treated with EscharEx achieved complete debridement within two weeks, compared to 0% for those treated with SANTYL. The median time to complete debridement was nine days for EscharEx; for SANTYL, that endpoint was not reached.
Collagenase SANTYL ointment, introduced in 1965, still generates an estimated $400 million in annual U.S. sales — the only widely used enzymatic debridement product in the market. A therapy unchanged in six decades commanding that kind of share is either a fortress or an invitation. Based on what's in front of us, MediWound is treating it as the latter.
The growing collaborator list — Coloplast/Kerecis, ConvaTec, Essity, Mölnlycke, Solventum, MIMEDX, and most recently B. Braun — signals commercial positioning, not just academic partnership. The VALUE global Phase III trial for VLUs is enrolling across 40 sites in the U.S. and Europe, with an interim analysis expected in mid-2026 after 65% of patients complete treatment. That interim is the next hard catalyst.
The BTK read: The SANTYL dominance story has always rested on incumbency, not clinical superiority. That pillar is being systematically removed. The mid-2026 VALUE interim will be watched by every major wound care commercial and BD team in the industry. The B. Braun collaboration signals MediWound understands the urgency of commercial positioning ahead of the readout.
Commercial | Sanuwave Q1: The Floor Is Becoming Clearer
Sanuwave Health (NASDAQ: SNWV) reported preliminary Q1 2026 revenue of $9.6–$9.7 million, a 3–4% increase versus Q1 2025 and in line with prior guidance, but at the lower end of the range after several meaningful deals slid out of the quarter. The constructive read from management: the patients and the wounds have not gone away and the need for care remains.
Sanuwave's UltraMIST reimbursement sits materially outside the CAMP disruption zone. Full Q1 results are expected in May.
The BTK read: Sanuwave is one of the cleaner reads on where real procedural demand sits versus where inflated utilization was. The companies with clinical differentiation, stable reimbursement, and execution track records benefit first as the market normalizes.
Corporate | MiMedx Restructures — $40M Cost Cut Confirms Reimbursement Pressure Is Structural
This one matters beyond MiMedx. MiMedx announced a restructuring to reduce annual operating expenses by approximately $40 million, eliminated its Chief Operating Officer role, and expects a one-time $4 million restructuring charge in Q2 2026. CEO Joseph Capper stated that while the Surgical business continues to flourish, the Wound Care business, along with the broader market, is recovering from the January 1 Medicare reimbursement reduction at a very slow rate.
The CEO's base salary was cut 20%; other named executive officers reduced by 10% through year-end. That's not a performance gesture — that's a leadership team signaling shared accountability for a business environment that isn't recovering on schedule.
The BTK read: MiMedx's restructuring is the most explicit confirmation yet that Q1 2026 wound care recovery is lagging expectations across the sector — not just for one company. The surgical business is being prioritized for investment; the wound care business is being right-sized for a slower normalization timeline. Read this as a sector-level signal, not a company-specific failure.
Global | Europe's Wound Care Reckoning: Industry Calls for Policy Action
Mölnlycke welcomed the publication of "Shaping the Future of Wound Care in Europe," the first joint industry white paper from the MedTech Europe Wound Care Sector Working Group, urging EU policymakers to elevate wound care as a strategic health priority across the EU. Across Europe, up to 14.9 million people suffer from chronic wounds, placing a significant and often overlooked burden on patients, caregivers, and health systems. Chronic wound care consumes up to 4% of European healthcare budgets, driven by delayed diagnosis, prolonged treatment, preventable complications, and workforce strain.
Despite this scale, chronic wounds remain under-recognised in policy and are often treated as secondary concerns — even though conditions such as diabetic foot ulcers carry a five-year mortality rate comparable to certain cancers.
The white paper identifies three priority areas for coordinated European action: prevention and patient-centered care built around evidence-based, holistic approaches; workforce capacity through multidisciplinary teams, standardized training, and digital tools; and policy and system-level coordination that aligns reimbursement and procurement with patient outcomes, supported by stronger real-world evidence. The call to action is direct — chronic wounds are preventable, but they become chronic when prevention, early intervention, and coordinated care fall short.
The backdrop matters. Mölnlycke's CEO Zlatko Rihter resigned in late March, with CFO Guillaume Joucla appointed interim CEO while the Board initiates a permanent search. A leadership transition at one of the most operationally central companies in the European wound care ecosystem — an EscharEx clinical collaborator, EWMA co-presenter, and co-lead of the MedTech Europe Wound Care Sector Working Group — is worth watching as EWMA Bremen approaches in two weeks.
The BTK read: What's unfolding in the U.S. with CMS restructuring is not unique to this market. Europe is on a parallel trajectory, but earlier in the arc. The white paper signals that industry is not waiting for the crisis to fully land before building the policy infrastructure to respond to it. The framing here - chronic wounds as a mortality-level public health concern, not a niche clinical subspecialty - is the argument that moves policymakers. For companies with European commercial operations or expansion plans, this is the beginning of a multiyear advocacy and reimbursement alignment cycle. The companies that show up to that conversation early will have a structural advantage over those that wait for the policy to find them.
VASCULAR & LIMB SALVAGE
Clinical | Efemoral Drops Three-Year Data — and It Changes the Femoropopliteal Conversation
At the Charing Cross Symposium in London, Efemoral Medical presented three-year results from the EFEMORAL I first-in-human trial of the Efemoral Vascular Scaffold System, demonstrating 97% primary patency, 97% freedom from target lesion revascularization, and 1% post-procedural residual stenosis — the lowest rate ever reported in a femoropopliteal clinical trial.
The EVSS is a bioresorbable scaffold with long-term sirolimus elution designed to restore normal vessel diameter, accommodate lower extremity tortuosity via its FlexStep Technology, and leave no permanent implant behind. Up to 50% of conventional endovascular femoropopliteal procedures have historically been complicated by failure or recurrence — three-year data at 97% patency from a dissolving platform is a meaningful departure. The EVSS holds FDA Breakthrough Device designation for infrapopliteal artery lesions in CLTI patients.
The BTK read: If these results hold at scale, this technology has the potential to reframe BTK endovascular standard of care in CLTI. Watch for the pivotal trial design and U.S. regulatory pathway.
AI & INNOVATION
Research | AI Designs a New Antibiotic — and Tests It on a Wound Infection
Researchers at McMaster University published results today for SyntheMol-RL, a generative AI model trained to explore up to 46 billion possible compounds. The model generated a novel antibiotic candidate called synthecin, formulated as a topical cream and tested on an otherwise drug-resistant wound infection in mouse models — where it was highly effective at controlling the infection. Unlike prior iterations, the model was designed to simultaneously optimize for both antibacterial activity and water solubility, resolving a core conflict that had limited prior AI antibiotic candidates' clinical viability.
The BTK read: Not a commercial story yet — mechanism-of-action studies are ongoing. But a generative AI platform that designs synthesizable, clinically viable antibacterial compounds from a 46-billion-compound chemical space is a structural capability, not a one-time finding. The wound care antimicrobial resistance problem is real and growing. Track this.
Q1 2026 EARNINGS WATCH
The sector enters its most consequential reporting stretch of the year. Every major wound care and limb salvage name reports Q1 results against the backdrop of the January 1 CMS reimbursement reset. This is the first full quarter where the CAMP restructuring impact is fully visible in the numbers. Here's what's on deck and what to watch:
MiMedx (NASDAQ: MDXG) — Reports April 29 This is the most anticipated read in the sector. The restructuring announcement already signaled slow wound care recovery, with the company reducing annual operating expenses by approximately $40 million and eliminating its COO role. The call will provide the first hard Q1 numbers and full commentary on the cost reduction roadmap. Watch for guidance language on when the wound care business is expected to stabilize.
Organogenesis (NASDAQ: ORGO) — Reports May 7 One of the most direct reads on the CTP reimbursement environment. Organogenesis has been under sustained pressure around skin substitute utilization and reimbursement scrutiny. Q1 will either confirm the floor or extend it. Revenue trajectory and gross margin performance are the two numbers that matter.
Treace Medical Concepts (NASDAQ: TMCI) — Reports May 13 Treace rebounded sharply after sustained pressure. Q1 will test whether Lapiplasty procedure volume is recovering and whether the commercial model is scaling as expected. This is a foot-and-ankle read, not a wound care one — but it matters for the BTK surgical corridor.
Avita Medical (NASDAQ: RCEL) — Reports May 14 AVITA reports against the backdrop of exceptional Cohealyx interim data and a +34% prior-week move. The question now is whether Q1 commercial momentum in RECELL justifies the rerating. Burn center utilization, new accounts, and the Cohealyx enrollment update are the key signals to watch.
Sanuwave Health (NASDAQ: SNWV) — Full Q1 Report Expected May The preliminary $9.6–$9.7M figure is already in the market. The full call will add color on the pipeline of deals that slid out of Q1, full-year guidance reaffirmation, and how the competitive landscape is shifting as CTP players retrench.
What to watch across the board: Every management team will be asked the same questions — where is the reimbursement floor, when does utilization return, and what is the 2026 exit rate? The variance in answers will tell you everything about which companies have real visibility and which ones are hoping for a macro tailwind that may not arrive on schedule.
📅 UPCOMING EVENTS
May 1–2 | Teaneck, NJ Desert Foot East Conference — Marriott at Glenpointe Evidence-based limb salvage, advanced wound care, and surgical and medical disorders of the lower limb. Strong podiatric faculty.
May 6–8 | Bremen, Germany 🔥 EWMA-DEWU 2026 — Messe Bremen The 36th European Wound Management Association Congress, co-hosted with the German Wound Congress. 5,000+ attendees, 150+ exhibitors. MediWound presenting EscharEx data here. The must-attend European wound care event of 2026.
May 14–15 | Austin, TX 🔥 Advanced Wound Care Summit (AWCS) — Marriott Downtown The business of wound care — investors, BD leaders, payors, distributors, multinationals, regulators. CAMP diversification, CEO panels, and post-reimbursement market forecasting. The room to be in for commercial and investor audiences in May.
May 31–June 2 | WOCNext 2026 The WOCN Society's annual clinical gathering. Ostomy, continence, and wound care; strong nursing and advanced practice track. Registration is open.
June 21 | St. Louis, MO St. Louis Wound & Vascular Symposium — Hilton Frontenac One-day regional focused on vascular surgery in wound care and complex lower extremity cases.
August 6–9 | Nashville, TN 🔥 APMA Annual Scientific Meeting (The National) — Gaylord Opryland The national gathering for podiatric medicine. Four full days. Essential for anyone selling into or tracking the podiatric channel. Wound care, surgery, biomechanics, and reimbursement all on the agenda.
September 10–11 | New Orleans, LA 🔥 IPAWS & Tissue Repair Summit (Kernexus) — The Ritz-Carlton Three tracks: tissue repair, post-acute and mobile wound care, and CAMPs market dynamics. The post-acute wound care community's primary gathering.
September 23–27 | Kuala Lumpur, Malaysia 🔥 World Union of Wound Healing Societies (WUWHS) 2026 — Kuala Lumpur Convention Centre The quadrennial global congress of the wound healing community. The single largest international wound care event in the calendar — and its Asia-Pacific location reflects precisely where the growth arc is pointing.
October 15–18 | Las Vegas, NV 🔥 SAWC Fall 2026 — Caesars Palace Co-located with the NPIAP Fall Conference. New for 2026: a dedicated Mobile Wound Care Track reflecting the accelerating shift toward home and post-acute delivery. 50+ sessions, 55+ faculty. The full wound care team's fall gathering.
October 22–24 | Anaheim, CA 🔥 DFCon 2026 — JW Marriott Anaheim Resort ALPS's global interdisciplinary diabetic foot conference. Premier first-look venue for next-generation endovascular therapies, AI diagnostics, and regenerative biologics in the diabetic foot and limb preservation space.
December 9–12 | Phoenix, AZ Desert Foot Multi-Disciplinary Limb Salvage & Wound Care Conference — Sheraton Phoenix Downtown The flagship annual limb salvage conference. Federal service, VA, DOD, private sector, and podiatric residency communities. Strong hands-on workshop format.
Not subscribed yet? → [Click here] Forward this to one person in your network who works in this space. Below The Knee | belowtheknee.co Independent market intelligence for wound care, limb salvage, and foot & ankle.
See you next week.
-Scott